for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Vir Biotechnology Inc

VIR.OQ

Latest Trade

36.89USD

Change

-0.46(-1.23%)

Volume

143,578

Today's Range

36.24

 - 

37.35

52 Week Range

25.31

 - 

141.00

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
37.35
Open
37.35
Volume
143,578
3M AVG Volume
15.02
Today's High
37.35
Today's Low
36.24
52 Week High
141.00
52 Week Low
25.31
Shares Out (MIL)
130.04
Market Cap (MIL)
4,856.99
Forward P/E
-15.73
Dividend (Yield %)
--

Next Event

Q2 2021 Vir Biotechnology Inc Earnings Release

Latest Developments

More

Singapore Health Regulator Grants Interim Authorisation For Glaxosmithkline's Sotrovimab For Treatment Of Covid-19 Infection

GSK, Vir Biotechnology To Supply sotrovimab To Govt of Singapore

Vir Biotechnology Presents New Clinical Data From Ongoing Trials Of Vir-2218 And Vir-3434 In Patients With Chronic Hepatitis B Virus Infection At The International Liver Congress 2021

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Vir Biotechnology Inc

Vir Biotechnology, Inc. is a clinical-stage immunology company. The Company is focused on developing treatments to treat and prevent serious infectious diseases. Its technology platforms are focused on antibodies, T cells, innate immunity and small interfering ribonucleic acid (siRNA). Its pipeline consists of product candidates targeting hepatitis B virus (HBV), influenza A, human immunodeficiency virus (HIV) and tuberculosis (TB). Its product candidates include VIR-2218, VIR-3434, VIR-2482, VIR-1111 and VIR-2020. The Company is developing VIR-2218 and VIR-3434 for the functional cure of HBV. VIR-2218 is a subcutaneously administered HBV-targeting siRNA. VIR-3434 is a subcutaneously administered HBV-neutralizing monoclonal antibody (mAb). VIR-2482 is an intramuscularly administered influenza A-neutralizing mAb. VIR-1111 is a subcutaneously administered HIV T cell vaccine. VIR-2020 is a subcutaneously administered TB T cell vaccine.

Industry

Biotechnology & Drugs

Contact Info

499 Illinois St Ste 500

SAN FRANCISCO, CA

94158-2521

United States

+1.415.9064324

https://www.vir.bio/

Executive Leadership

Vicki L. Sato

Independent Chairman of the Board

George A. Scangos

President, Chief Executive Officer, Director

Howard Horn

Chief Financial Officer, Secretary

Herbert Whiting Virgin

Executive Vice President of Research and Chief Scientific Officer

Ann M. Hanly

Chief Technology Officer

Key Stats

2.25 mean rating - 8 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2019

0.0K

2020

0.1K

2021(E)

0.3K
EPS (USD)

2019

-5.760

2020

-2.510

2021(E)

-2.375
Price To Earnings (TTM)
--
Price To Sales (TTM)
66.88
Price To Book (MRQ)
7.45
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-65.32
Return on Equity (TTM)
-48.41

Latest News

Latest News

Italy approves GSK-Vir antibody to treat COVID-19

Italy approved the temporary distribution of a coronavirus antibody treatment by Britain's GlaxoSmithKline and U.S. company Vir Biotechnology, the health ministry said in a statement on Tuesday.

Study confirms GSK-Vir antibody drug reduces hospitalization, death in COVID-19 patients

GlaxoSmithKline Plc and Vir Biotechnology said on Monday final results from a late-stage study of their monoclonal antibody confirmed it significantly reduced hospitalization and death among high-risk COVID-19 patients when given early in the disease.

U.S. FDA gives emergency use approval for GSK-Vir COVID-19 antibody drug

The U.S. Food and Drug Administration gave an emergency use authorization to the antibody treatment developed by Vir Biotechnology and GlaxoSmithKline for treating mild-to-moderate COVID-19 in people aged 12 years and older.

U.S. FDA gives emergency use approval to GSK-Vir COVID-19 antibody drug

The U.S. Food and Drug administration on Wednesday gave an emergency use authorization to the COVID-19 antibody treatment developed by Vir Biotechnology Inc and GlaxoSmithKline. (https://bit.ly/3uorQZ8) (Reporting by Amruta Khandekar; Editing by Shounak Dasgupta)

EU regulator backs use of GSK-Vir antibody to treat COVID-19

The European Union's drug regulator said on Friday a COVID-19 antibody treatment developed by GlaxoSmithKline and Vir Biotechnology can be used to treat patients who are at risk of severe disease and do not need supplemental oxygen.

EU regulator permits use of GSK-Vir antibody to treat COVID-19

The European medicines regulator said on Friday a COVID-19 antibody treatment developed by GSK and Vir Biotechnology can be used to treat patients who are at risk of severe disease and do not need supplemental oxygen.

EMA starts review of GSK's monoclonal antibody to treat COVID-19 patients

The European Medicines Agency said on Thursday it is reviewing available data on the use of GlaxoSmithKline's monoclonal antibody to treat COVID-19 patients.

UPDATE 2-EMA starts review of GSK's monoclonal antibody to treat COVID-19 patients

The European Medicines Agency said on Thursday it is reviewing available data on the use of GlaxoSmithKline's monoclonal antibody to treat COVID-19 patients.

Lilly-Vir's COVID-19 antibody combo reduces viral load in study

Antibody treatments from Eli Lilly and Vir Biotech reduced viral load in low-risk COVID-19 patients, results from a mid-stage trial showed on Monday.

Lilly-Vir's COVID-19 antibody combo reduced viral load in study

Eli Lilly, Vir Biotech and partner GlaxoSmithKline said on Monday Lilly's antibody therapy in combination with Vir's antibody drug candidate reduced viral load in low-risk COVID-19 patients in a mid-stage trial.

GSK and Vir seek emergency use of COVID-19 therapy in United States

GSK and Vir Biotechnology have filed an application to U.S. regulators for emergency use authorization of their antibody therapy to treat early-stage COVID-19 infections, the drugmakers said on Friday.

GSK, Vir apply for U.S. emergency use of COVID-19 antibody therapy

GSK and Vir Biotechnology have filed an application to U.S. regulators for emergency use authorization of their antibody therapy to treat early-stage COVID-19 infections, the drugmakers said on Friday.

Vir, GSK to seek emergency use clearance for COVID-19 antibody therapy

Vir Biotechnology and Britain's GSK plan to seek emergency use authorization for their experimental COVID-19 antibody therapy after interim data from a study showed 85% reduction in hospitalization and deaths among patients, the companies said.

Vir, GSK's COVID-19 antibody trial shows 85% drop in hospitalization or death

Interim data from a late-stage study of their experimental COVID-19 antibody therapy showed an 85% reduction in hospitalization or death in patients, Vir Biotechnology Inc and GlaxoSmithKline Plc said on Thursday.

Vir, GSK to halt enrollment in U.S. COVID-19 antibody trial sub-study

Vir Biotechnology and Britain's GSK said on Wednesday they would pause enrollment into a study testing their experimental COVID-19 antibody therapy, which is a part of a large U.S. trial.

GSK, Vir Biotech to expand COVID-19 research partnership for other diseases

GlaxoSmithKline and Vir Biotechnology Inc will expand an existing partnership developing antibody therapies for COVID-19 to other diseases, the companies said on Wednesday.

GSK, Vir Biotech to expand COVID-19 research partnership for other diseases

British drugmaker GlaxoSmithKline Plc and Vir Biotechnology Inc will expand their existing partnership developing antibody therapies for COVID-19 to research therapies for other diseases, the companies said on Wednesday.

UPDATE 1-Eli Lilly testing COVID-19 antibody treatment with Vir Biotech's drug

Eli Lilly and Co is testing its COVID-19 antibody therapy in combination with another treatment by Vir Biotechnology Inc and its partner GlaxoSmithKline , in an effort to combat new variants of the coronavirus.

Eli Lilly to test COVID-19 antibody treatment with Vir Biotech's drug

Eli Lilly and Co said on Wednesday it would test a combination of its COVID-19 antibody therapy with another treatment by Vir Biotechnology Inc and its partner GlaxoSmithKline.

GSK, Vir to test antibody for COVID-19 treatment

British drugmaker GSK and U.S.-based Vir Biotechnology will evaluate a second antibody-based treatment in patients with mild to moderate COVID-19 in an early- to mid-stage trial, the companies said on Tuesday.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up